Jump to content

AAH


colaiscute

Recommended Posts

Arana Files IND for Lead Anti-Inflammatory Product ART621

 

View announcement at arana.com

 

Tuesday, 30 September 2008 Sydney, Australia:

 

ART621 IND for rheumatoid arthritis indication submitted to FDA

Phase II RA trial anticipated to commence in late Q4/2008

Biotechnology company Arana Therapeutics Limited (ASX: AAH) today announced it has submitted an Investigational New Drug application (IND) to the FDA (U.S. Food and Drug Administration) for the anti-inflammatory product ART621 in a rheumatoid arthritis (RA) indication.

 

The IND includes a Phase II dose ranging study of ART621/221 in RA which is planned to be an international multi-centred trial of approximately 200 patients.

 

The study is designed to establish the appropriate dosing for ART621 in RA and will compare three doses of ART621 with a placebo in patients also taking methotrexate. Arana expects to commence recruitment for the study in late quarter 4 2008, subject to FDA feedback.

 

Taking into account their global expertise and experience, the management of the study has been awarded to Quintiles Transnational, the worldÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s largest contract research organisation.

 

Commenting on these developments, CEO John Chiplin said: ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“We are very excited that ART621 has reached this important milestone - being AranaÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s first IND. We are now a confirmed clinical stage company and with our strong pipeline look forward to filing more INDÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s in the future.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ

 

Ends

 

About Arana Therapeutics:

 

Arana Therapeutics (ASX: AAH) is an international biopharmaceutical company focussed on developing next generation antibody based drugs that will improve the lives of patients with inflammatory diseases and cancer.

 

Arana TherapeuticsÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ innovative engineering technologies provide the basis for developing its next generation antibody candidates. Arana Therapeutics has the financial strength and management expertise to develop its product pipeline.

 

Arana has a significant track record of commercialising its technologies and has partnerships with GSK, CSL, Centocor (J&J) and Abbott Laboratories.

 

Additional information:

 

ART621 is an ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“anti-TNFÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ - a class of drugs used for the treatment of inflammatory diseases such as rheumatoid arthritis, psoriasis and CrohnÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s disease. ART621 works by blocking the action of TNF (tumour necrosis factor) a protein which is involved in the generation of inflammation

 

 

 

For further information: www.arana.com

 

 

Link to comment
Share on other sites

  • Replies 9.7k
  • Created
  • Last Reply

Top Posters In This Topic

So what if anything can we make of announcements over the last month? 621 in current form working on rheumatoid arthritis in current trial , but needs tweaking for optimum performance in psoriasis, hence the new variation ART123 or is it as stated in the announcement a new drug altogether? They must of known the doubt this announcement would generate with regard to the current trial for psoriasis of 621? Surely ! As usual with this mob clear as mud! Is it to hide the true level of incompetence? Or are they deliberately trying to drive share down? For if they are, they are competent after all. Do we need a business mind running this business taking advice from a competent scientist? I'm thinking it's time to change to someone with a sense of timing.
Link to comment
Share on other sites

Are we in a trading halt at the moment. My Westpac account is saying AAH is in pre-open.

Maybe someone has worked out they can buy us for nothing and get the pipeline for free!!

 

http://www.sharescene.com/html/emoticons/grrr.gifhttp://www.sharescene.com/html/emoticons/grrr.gif

Link to comment
Share on other sites

QUOTE (gools @ Thursday 02/10/08 11:24am)

no gools ASX announcement..

 

ARANA COMPLETES A SERIES OF HUMANISED AND IMPROVED ANTIBODIES FOR VEGENICSÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ CANCER TREATMENT PROGRAMÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢

 

Arana successfully completes humanisation and optimisation of VegenicsÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ (a wholly owned subsidiary of Circadian) VEGF-D product

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢

An important milestone achieved in the development of VEGF-D antibody for VegenicsÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ cancer treatment program

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢

Preset success criteria have been met, triggering a success-based payment to Arana

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢

Fourth partner product successfully engineered by Arana using its proprietary technologies

Antibody therapeutics company Arana Therapeutics Limited (ASX:AAH) and biologics drug development company Circadian Technologies Limited (ASX:CIR) today announced that Arana has successfully engineered an improved version of the VEGF-D antibody (VGX-200) owned by CircadianÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s 100% subsidiary Vegenics, for the treatment of solid cancers.

Arana utilised its proprietary SuperhumanisationTM technology to successfully develop humanised versions of VegenicsÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ VEGF-D lead mouse antibody. The purpose of converting a non-human antibody into a human-like antibody is so that it may be safely administered to patients minimising the risk of rejection of the treatment. The potency of these candidates was then further improved using AranaÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s EvoGeneTM optimisation technology. The success of this project triggers a final instalment of research costs to Arana under the terms of the collaboration agreement between the two companies. In addition, Arana will receive a milestone payment for successfully meeting the improvement criteria set at the outset of the project.

Vegenics will now conduct further pre-clinical studies on the series of humanised and improved VEGF-D antibody drug candidates. Upon designation by Vegenics of a lead drug candidate a further milestone will become payable to Arana. Arana is then eligible to earn further milestone payments as the product advances through subsequent stages of pre-clinical and clinical testing and regulatory approval and a royalty on product sales.

Vegenics has accumulated a strong patent portfolio covering drugs directed against VEGF-D. VEGF-D is closely related to VEGF-A, the target of GenentechÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s AvastinÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚®, a leading cancer therapy with worldwide sales in 2007 in excess of US$6 billion.

Circadian and Vegenics CEO, Robert Klupacs said ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“The achievement of this humanisation milestone is an important step in our ongoing development of anti-VEGF-D antibodies as potential therapeutic candidates for the treatment of cancer. Consistent with our strategy this humanised VEGF-D antibody expands our cancer drug development program, which includes our existing human VEGF-C cancer drug candidate VGX-100.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ

Arana CEO, Dr John Chiplin, said ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“This is the fourth product that we have significantly improved and delivered back to a collaboration partner using our proprietary technologies which improve antibody and protein products. This represents an impressive 100% track record of success and we look to continue to build on this as we move forward with other partners.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ

Arana has already successfully engineered products from the biopharmaceutical pipelines of both CSL Limited and pharmaceutical giant GlaxoSmithKline (GSK). Arana also has an ongoing alliance with US-based Aveo Pharmaceuticals Inc for the use of AranaÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s SuperhumanisationTM technology for the internal development of several Aveo drug products.

Link to comment
Share on other sites

AAH Next maybe?????????

 

 

INDIANAPOLIS_Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co. http://www.sharescene.com/html/emoticons/sadsmiley02.gifhttp://www.sharescene.com/html/emoticons/sadsmiley02.gif

 

Link to comment
Share on other sites

Sorry,

http://www.sharescene.com/html/emoticons/wub.gifhttp://www.sharescene.com/html/emoticons/biggrin.gif

Full Article

 

News Article

Eli Lilly to Buy ImClone for More Than $6B

 

AP Online - Oct. 06, 2008

 

INDIANAPOLIS_Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co.

 

Indianapols-based Lilly announced Monday that it will pay $70 per share for ImClone. New York-based Bristol-Myers then said it would not increase its latest offer of $62 per share.

 

Lilly executives said the ImClone deal would expand Lilly's cancer treatment pipeline a few years before several significant patent expirations hit the drug maker. Lilly CEO John Lechleiter said the deal would create a "true oncology powerhouse" by combining his company's cancer drugs and resources with ImClone's.

 

"This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry," Lechleiter said during a Monday morning conference call with analysts.

 

Wall Street, however, reacted coolly, dropping Lilly's share price by 5 percent to $39.16 in Monday morning trading. ImClone shares, meanwhile, rose nearly 3 percent to $66.73.

 

New York-based ImClone had previously rejected as too low two takeover offers from Bristol-Myers, which gets a share of sales from the cancer drug Erbitux.

 

Indianapolis-based Lilly's $70-per-share offer is more than 50 percent over ImClone's price in July before Bristol-Myers made its first bid of $60 per share.

 

Bristol-Myers CEO James Cornelius, a former Lilly executive, said in a statement his company was "pleased to have initiated a process that has resulted in the substantial increase of ImClone's value for all of its stockholders."

 

Bristol-Myers owns more than 14 million ImClone shares, and the deal will be worth about $1 billion in cash for the New York-based drug maker.

 

Lilly will finance the deal through a combination of cash and up to $3 billion in debt.

 

Both boards have approved and recommended that ImClone stockholders tender their shares.

 

With about 87 million shares outstanding as of Aug. 1, that would amount to nearly $6.1 billion. Lilly said in its news release that the transaction is worth $6.5 billion.

 

Lilly spokesman Mark Taylor said $6.5 billion is the estimated gross cost of the transaction. That figure assumes a fully diluted share base, including stock options that vest. It does not include ImClone debt or cash on hand.

 

Bristol-Myers, which owns about 17 percent of ImClone's shares, had previously offered $60 a share and later $62 per share for the part of ImClone it doesn't already own. Bristol-Myers Squibb had no immediate comment on the Lilly offer Monday.

 

Lechleiter said he hopes the deal will close by the end of the year or in the first quarter of 2009.

 

ImClone said its chairman, Carl Icahn, who owns about 14 percent of ImClone stock, has agreed to vote in favor of the Lilly deal.

 

The deal will add Erbitux, a treatment for colorectal and head and neck cancers, to Lilly's portfolio of cancer drugs. They include the lung cancer and mesothelioma treatment Alimta, and chemotherapy agent Gemzar.

 

Lilly officials said the ImClone addition helps it meet challenges posed by several looming patent expirations. The drug maker loses patent protection on its top-seller, the anti-psychotic Zyprexa, in 2011.

 

Zyprexa contributed more than a quarter of the company's $18.6 billion in sales last year. The company then will lose patent protection for its second- and third-best selling drugs, the antidepressant Cymbalta and Gemzar, in 2013.

 

Erbitux could be approved for additional treatments, and Lilly also identified three ImClone drug candidates as particularly promising: IMC-112B, IMC-A12 and IMC-11F8.

 

The 112B drug is designed to kill tumors by preventing the growth of the blood vessels that feed them, similar to Genentech Inc.'s cancer drug Avastin.

 

The 11F8 drug is an antibody that targets production of a protein found on the surface of many cancer cells. That protein, epidermal growth factor receptor, is also targeted by Erbitux.

 

The 112B drug is in late-stage testing as a treatment for metastatic breast cancer. Late-stage trials of the other drug candidates in a variety of indications could start in 2009.

 

Analysts expressed concern during the conference call about Bristol-Myers' potential rights over the 11F8 molecule. But Lilly officials said the deal doesn't hinge on that compound.

 

"This deal will be financially successful with the income stream of Erbitux, including future new indications, accompanied by one additional successful drug from the current crop of five clinical candidates," said Lilly Chief Financial Officer Derica Rice.

 

Everyone involved in this deal came out a winner, according to Eric Gordon, director of biomedical industry's programs at Stevens Institute of Technology.

 

Lilly gets "a prize," the portion of ImClone's pipeline not covered by collaboration agreements, which Lilly needs because its early-stage pipeline of cancer drugs is not as strong as it wants, according to Gordon.

 

Carl Icahn and ImClone shareholders win by getting a higher share price, as does Bristol-Myers Squibb, which owns 17 percent of ImClone shares. Before Bristol-Myers made its offer, ImClone's share price "was wandering around in the low 40s," Gordon noted.

 

"It should be enough to soothe (Bristol-Myers) CEO Jim Cornelius's disappointment, especially since the valuable collaboration agreement regarding Erbitux stays in place" unless Lilly offers enough to buy out Bristol's rights, Gordon concluded.

 

ImClone was the company at issue when homemaking mogul Martha Stewart was sent to prison for lying about the sale of ImClone stock on a tip just before the Food and Drug Administration in 2001 denied ImClone's application to sell Erbitux.

 

 

Link to comment
Share on other sites

Arana Strengthens Board with New Appointment

 

9 October 2008

 

Biotechnology company Arana Therapeutics Limited

 

(ASX: AAH) today announced the appointment of Gordon Black as a non-independent non-executive director of the company.

Mr Black is managing director of Biofusion Capital (a significant shareholder of Arana), a specialist life sciences venture capital fund and an early stage investor in EvoGenix Limited. He is associated with AranaÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s major shareholder Yap Lim Sen.

Robin Beaumont, Chairman of Arana said ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Gordon Black brings a wealth of experience to the Arana board, in particular through his connections in the biotechnology industry.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“We believe the year ahead will provide significant opportunities for Arana to deliver further results from its clinical programs. GordonÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s expertise will be particularly useful as we move into the next phase of growth for the company,ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ he added.

Mr Black has over 20 yearsÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ experience in the life sciences sector and has worked in the USA, the Asia Pacific region and Australia for corporations operating in the investment banking, life sciences and real estate investment industries including, J.B.Were, Merrill Lynch New York, E.I. Du Pont de Nemours & Co. Inc (in the global head office, Wilmington Delaware, USA and Asia Pacific) and Ipoh Limited Sydney.

 

Link to comment
Share on other sites

In reply to: theadder on Thursday 09/10/08 09:51am

some info' on Mr Gordon Black

 

Mr Gordon Black is actively involved in the development of the Australian life sciences industry.

Mr. Black co-founded BioFusion Capital Pty Limited in 2002, a venture capital fund focused on developing Australian life science companies with promising global growth potential. BioFusion Capital along with Start-up Australia was an early stage investor in EvoGenix Pty Limited prior to ASX listing in August 2005 and the merger with Peptech Limited in August 2007 to form Arana Therapeutics Limited.

In addition, Mr. Black co-founded East West Capital Limited in 2005, a special funds management company, investing in Australian listed equities for Australian and international sophisticated investors ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ particularly companies operating in the life sciences sector.

Prior to co-founding these companies, Mr. Black worked in the US and Asia Pacific with Merrill Lynch, New York in capital markets and with Du Pont in the global chemical industry in their US head office Wilmington, Delaware, as Senior Analyst Special Projects and later in Corporate Planning supporting the Du Pont global business units operating in the Asia Pacific region.

After returning to Sydney, Mr. Black in 1994 joined the ASX listed property investment company Ipoh Limited. As Director ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ Corporate Services, he reported to the Managing Director and was responsible for capital raising, investment and strategic planning prior to the company being acquired by the Government Investment Corporation of Singapore in 2001.

Mr. Black holds a Master of Business Administration from the Wharton School, University of Pennsylvania and a BSc in Biochemistry/Chemistry from the University of New South Wales and has a strong background in strategic planning, finance and investment

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...